

Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/CA6A42F7D74EN.html

Date: March 2021

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: CA6A42F7D74EN

Abstracts

Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Corcept Therapeutics Inc (Corcept) discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company's marketed product, Korlym (mifepristone) a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome. Corcept's major pipeline products include relacorilant for endogenous cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder among other disorders. Corcept is headquartered in Menlo Park, California, the US.

Corcept Therapeutics Inc Key Recent Developments

Mar 01,2021: Corcept Therapeutics expands executive team; Atabak Mokari joins as

Chief Financial Officer; Charles Robb named Chief Business Officer

Feb 23,2021: Corcept Therapeutics announces fourth quarter and full-year 2020

audited financial results

Feb 08,2021: Corcept Therapeutics announces fourth quarter, full-year 2020 preliminary



selected financial results and 2021 revenue guidance; Provides corporate update Nov 23,2020: Corcept Therapeutics appoints Gillian M. Cannon, PhD, to Board of Directors

Nov 03,2020: Corcept Therapeutics announces third quarter 2020 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,



financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Corcept Therapeutics Inc - Key Facts

Corcept Therapeutics Inc - Key Employees

Corcept Therapeutics Inc - Key Employee Biographies

Corcept Therapeutics Inc - Major Products and Services

Corcept Therapeutics Inc - History

Corcept Therapeutics Inc - Company Statement

Corcept Therapeutics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Corcept Therapeutics Inc - Business Description

Corcept Therapeutics Inc - SWOT Analysis

SWOT Analysis - Overview

Corcept Therapeutics Inc - Strengths

Corcept Therapeutics Inc - Weaknesses

Corcept Therapeutics Inc - Opportunities

Corcept Therapeutics Inc - Threats

Corcept Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021



Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Corcept Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Mar 01, 2021: Corcept Therapeutics expands executive team; Atabak Mokari joins as Chief Financial Officer; Charles Robb named Chief Business Officer

Feb 23, 2021: Corcept Therapeutics announces fourth quarter and full-year 2020 audited financial results

Feb 08, 2021: Corcept Therapeutics announces fourth quarter, full-year 2020 preliminary selected financial results and 2021 revenue guidance; Provides corporate update

Nov 23, 2020: Corcept Therapeutics appoints Gillian M. Cannon, PhD, to Board of Directors

Nov 03, 2020: Corcept Therapeutics announces third quarter 2020 financial results and provides corporate update

Aug 04, 2020: Corcept Therapeutics announces second quarter 2020 financial results and provides corporate update

Jul 14, 2020: Corcept Therapeutics: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers May 04, 2020: Corcept Therapeutics announces first quarter 2020 financial results and provides corporate update

Mar 12, 2020: Corcept Therapeutics appoints Gregg Alton to Board of Directors Feb 20, 2020: Corcept Therapeutics announces fourth quarter And full-year 2019 audited financial results and provides corporate update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Corcept Therapeutics Inc, Key Facts

Corcept Therapeutics Inc, Key Employees

Corcept Therapeutics Inc, Key Employee Biographies

Corcept Therapeutics Inc, Major Products and Services

Corcept Therapeutics Inc, History

Corcept Therapeutics Inc, Subsidiaries

Corcept Therapeutics Inc, Key Competitors

Corcept Therapeutics Inc, Ratios based on current share price

Corcept Therapeutics Inc, Annual Ratios

Corcept Therapeutics Inc, Annual Ratios (Cont...1)

Corcept Therapeutics Inc, Annual Ratios (Cont...2)

Corcept Therapeutics Inc, Interim Ratios

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Corcept Therapeutics Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Corcept Therapeutics Inc, Performance Chart (2016 - 2020)

Corcept Therapeutics Inc, Ratio Charts

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/CA6A42F7D74EN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CA6A42F7D74EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970